
Astronauts from India, Poland, Hungary launched on first space station mission
NASA retiree turned private astronaut Peggy Whitson was launched on the fifth flight to orbit of her career early Wednesday, joined by crewmates from India, Poland and Hungary heading for their countries' first visit to the International Space Station.
The astronaut team lifted off from NASA's Kennedy Space Center in Cape Canaveral, Florida, at about 2:30 a.m., beginning the latest mission organized by Texas-based startup Axiom Space in partnership with Elon Musk's rocket venture SpaceX.
The four-member crew was carried aloft on a towering SpaceX launch vehicle consisting of a Crew Dragon capsule perched atop a two-stage Falcon 9 rocket.
Live video showed the towering spacecraft streaking into the night sky over Florida's Atlantic coast, trailed by a brilliant yellowish plume of fiery exhaust.
Cameras inside the crew compartment beamed footage of the four astronauts strapped into their pressurized cabin, seated calmly side by side in helmeted white-and-black flight suits as their spacecraft soared toward space.
"We've had an incredible ride uphill," Whitson radioed back to the SpaceX mission control near Los Angeles as Falcon's upper stage delivered the crew capsule to its preliminary orbit about nine minutes after launch.
Dubbed "Grace" by the Axiom crew, the newly built Crew Dragon launched Wednesday was making its debut flight as the fifth vehicle of its kind in the SpaceX capsule fleet.
It also marked the first Crew Dragon flight since Musk briefly threatened to decommission the spacecraft after US President Donald Trump threatened to cancel Musk's government contracts in a high-profile political feud earlier in June.
Axiom 4's autonomously operated Crew Dragon was expected to reach the ISS after a flight of about 28 hours, then dock with the outpost as the two vehicles soar together in orbit some 400 kilometers above Earth.
If all goes according to plan, the Axiom 4 crew will be welcomed aboard the orbiting space laboratory Thursday morning by its seven current resident occupants -- three astronauts from the US, one from Japan and three cosmonauts from Russia.
Whitson, 65, and her three Axiom 4 crewmates -- Shubhanshu Shukla, 39, of India, Sławosz Uznanski-Wisniewski, 41, of Poland and Tibor Kapu, 33, of Hungary -- are slated to spend 14 days aboard the space station conducting microgravity research.
The mission stands as the fourth such flight since 2022 arranged by Axiom as the Houston-headquartered company builds on its business of putting astronauts sponsored by private companies and foreign governments into Earth orbit.
For India, Poland and Hungary, the launch marked a return to human spaceflight after more than 40 years and the first mission to send their astronauts to the International Space Station.
Billionaire Charles Simonyi, a Hungarian-born software designer who became a US citizen in 1982, has twice visited the ISS as a space tourist, in 2007 and 2009, hitching rides aboard Russian Soyuz capsules on both occasions.
But like many wealthy individuals from various countries who have paid their way for joyrides to space in recent years, Simonyi was not flying on behalf of his homeland or any government.
Kapu is part of his country's Hungarian to Orbit program, while Uznanski-Wisniewski is a Polish astronaut assigned to the European Space Agency. Both are designated as Axiom 4 mission specialists.
The participation of Shukla, an Indian air force pilot, is seen by India's space program as a kind of precursor to the debut crewed mission of its Gaganyaan orbital spacecraft, planned for 2027.
The Axiom 4 crew is led by Whitson, who retired from NASA in 2018 after a pioneering career that included becoming the US space agency's first female chief astronaut and the first woman to command an ISS expedition.
Now a consultant and director of human spaceflight for Axiom, she has logged 675 days in space, a US record, during three NASA missions and a fourth flight to space as commander of the Axiom 2 mission in 2023.
Wednesday's blast-off marked SpaceX's 18th human spaceflight since Musk's privately funded rocket company ushered in a new era for NASA five years ago, providing American astronauts their first rides to space from US soil since the end of the space shuttle era in 2011.
Axiom, a nine-year-old venture co-founded by NASA's former ISS program manager, is one of a handful of companies developing a commercial space station of its own intended to eventually replace the ISS, which NASA expects to retire around 2030. (Reuters)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 days ago
- Korea Herald
Astronauts from India, Poland, Hungary launched on first space station mission
NASA retiree turned private astronaut Peggy Whitson was launched on the fifth flight to orbit of her career early Wednesday, joined by crewmates from India, Poland and Hungary heading for their countries' first visit to the International Space Station. The astronaut team lifted off from NASA's Kennedy Space Center in Cape Canaveral, Florida, at about 2:30 a.m., beginning the latest mission organized by Texas-based startup Axiom Space in partnership with Elon Musk's rocket venture SpaceX. The four-member crew was carried aloft on a towering SpaceX launch vehicle consisting of a Crew Dragon capsule perched atop a two-stage Falcon 9 rocket. Live video showed the towering spacecraft streaking into the night sky over Florida's Atlantic coast, trailed by a brilliant yellowish plume of fiery exhaust. Cameras inside the crew compartment beamed footage of the four astronauts strapped into their pressurized cabin, seated calmly side by side in helmeted white-and-black flight suits as their spacecraft soared toward space. "We've had an incredible ride uphill," Whitson radioed back to the SpaceX mission control near Los Angeles as Falcon's upper stage delivered the crew capsule to its preliminary orbit about nine minutes after launch. Dubbed "Grace" by the Axiom crew, the newly built Crew Dragon launched Wednesday was making its debut flight as the fifth vehicle of its kind in the SpaceX capsule fleet. It also marked the first Crew Dragon flight since Musk briefly threatened to decommission the spacecraft after US President Donald Trump threatened to cancel Musk's government contracts in a high-profile political feud earlier in June. Axiom 4's autonomously operated Crew Dragon was expected to reach the ISS after a flight of about 28 hours, then dock with the outpost as the two vehicles soar together in orbit some 400 kilometers above Earth. If all goes according to plan, the Axiom 4 crew will be welcomed aboard the orbiting space laboratory Thursday morning by its seven current resident occupants -- three astronauts from the US, one from Japan and three cosmonauts from Russia. Whitson, 65, and her three Axiom 4 crewmates -- Shubhanshu Shukla, 39, of India, Sławosz Uznanski-Wisniewski, 41, of Poland and Tibor Kapu, 33, of Hungary -- are slated to spend 14 days aboard the space station conducting microgravity research. The mission stands as the fourth such flight since 2022 arranged by Axiom as the Houston-headquartered company builds on its business of putting astronauts sponsored by private companies and foreign governments into Earth orbit. For India, Poland and Hungary, the launch marked a return to human spaceflight after more than 40 years and the first mission to send their astronauts to the International Space Station. Billionaire Charles Simonyi, a Hungarian-born software designer who became a US citizen in 1982, has twice visited the ISS as a space tourist, in 2007 and 2009, hitching rides aboard Russian Soyuz capsules on both occasions. But like many wealthy individuals from various countries who have paid their way for joyrides to space in recent years, Simonyi was not flying on behalf of his homeland or any government. Kapu is part of his country's Hungarian to Orbit program, while Uznanski-Wisniewski is a Polish astronaut assigned to the European Space Agency. Both are designated as Axiom 4 mission specialists. The participation of Shukla, an Indian air force pilot, is seen by India's space program as a kind of precursor to the debut crewed mission of its Gaganyaan orbital spacecraft, planned for 2027. The Axiom 4 crew is led by Whitson, who retired from NASA in 2018 after a pioneering career that included becoming the US space agency's first female chief astronaut and the first woman to command an ISS expedition. Now a consultant and director of human spaceflight for Axiom, she has logged 675 days in space, a US record, during three NASA missions and a fourth flight to space as commander of the Axiom 2 mission in 2023. Wednesday's blast-off marked SpaceX's 18th human spaceflight since Musk's privately funded rocket company ushered in a new era for NASA five years ago, providing American astronauts their first rides to space from US soil since the end of the space shuttle era in 2011. Axiom, a nine-year-old venture co-founded by NASA's former ISS program manager, is one of a handful of companies developing a commercial space station of its own intended to eventually replace the ISS, which NASA expects to retire around 2030. (Reuters)


Korea Herald
4 days ago
- Korea Herald
Sejong University earns global recognition, ranks third domestically
Sejong University has been ranked third among Korean universities in the recent global university rankings, which evaluated over 2,250 institutions worldwide based on research output and international competitiveness. The Seoul-based university placed 238th overall, following Seoul National University and Yonsei University, which ranked 122nd and 234th, respectively. The rankings were compiled by US News & World Report, an American publication that annually evaluates universities across 13 indicators, including research reputation, publication and citation performance, and the extent of international collaboration. This marks the second consecutive year that Sejong has held the No. 3 position among Korean institutions in the assessment, while rising three places in the global ranking from the previous year. Specifically, Sejong University ranked 38th globally for the proportion of top 10 percent most-cited papers, and 89th for the share of top 1 percent most-cited papers. Its level of collaboration with international institutions was also highly rated. Sejong also earned global recognition for its academic departments, with water resources engineering ranked 35th, mathematics 51st, electrical and electronic engineering 70th, and artificial intelligence 99th. Sejong University President Um Jong-hwa attributed the results to the university's longstanding focus on strengthening its research capacity and global engagement. 'This outcome reflects our commitment to a research-driven education model, continued investment in research, and expansion of international collaboration,' Um said. 'We will continue to grow as a leading global research university that delivers academic excellence and social contributions.'
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F22%2Fnews-p.v1.20250622.6f347ba79b0f48699e57a8849a11dca7_T1.jpg&w=3840&q=100)
![[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75)
Korea Herald
7 days ago
- Korea Herald
[Bio USA] SK Biopharmaceuticals CEO highlights resilience, open innovation amid global shifts
Korea Herald correspondent BOSTON — SK Biopharmaceuticals CEO Lee Dong-hoon underscored the company's preparedness for potential US tariff changes and emphasized the critical role of open innovation in shaping the future of global pharmaceuticals. 'We've weathered volatility in our share price over the past year, but the impact of potential price cuts has been minimal,' Lee said Thursday during a press conference on the sidelines of the 2025 Bio USA. 'Our direct-to-market sales model remains fundamentally solid.' He recalled a particularly tense moment earlier this year when shifting US tariff policies posed logistical challenges. In April, the company rushed to transport finished products from Canada into the US before a new tariff deadline. 'When the final truck finally cleared customs, everyone burst into applause,' he recounted. To prevent such risks from recurring, the company now assembles finished products in Canada and ensures shipments cross the border ahead of any policy changes. Looking ahead, SK Biopharmaceuticals is evaluating Puerto Rico as a potential US-based manufacturing site, leveraging its status as a US territory and pharmaceutical hub. 'Canada is cost-effective for now, but we're preparing for every scenario,' Lee said, noting the company's tariff risk is now 'close to zero' for the year. Lee also expressed confidence in the company's long-term growth. 'We've already announced our goal to hit 1 trillion won ($728 million) in sales by 2029, and we're on track,' he said, citing consistent profitability since last year. A cornerstone of SK Biopharmaceuticals' strategy is open innovation. Instead of relying solely on internal research and development, the company is partnering with universities, biotech firms and research institutions. 'Major global pharmaceutical firms are moving away from in-house basic research, and so are we. When you can collaborate and generate results at a fraction of the cost, your possibilities expand," he explained. The CEO emphasized the importance of tapping into underutilized technologies at US universities and biotech startups to diversify the company's pipeline, moving beyond its core focus on epilepsy into areas like oncology. Artificial intelligence is another major focus area. Lee highlighted the company's work on EEG-based seizure prediction models in collaboration with European and South American partners, along with AI algorithm development trials currently underway in Korea. 'AI is no longer optional. It's essential in every part of the business,' he said. One standout partnership is with PhnyX Lab, whose AI-driven automation of clinical documentation significantly reduced paperwork. 'Even our US team, which was initially skeptical, was blown away,' Lee said, calling the shift 'Copernican' in scale for how it will reduce time and cost. The CEO also outlined plans to build a global digital platform for epilepsy patients — a space where patients and physicians can share experiences and insights. 'It's not about selling drugs,' he clarified. 'It's about collecting data to inform AI-powered marketing, drug development and clinical trial design.' The company is looking three to five years ahead, aiming to build an ecosystem where shared data drives innovation across functions. In the US, SK Biopharmaceuticals is intensifying its engagement with health care providers. Lee has personally met with dozens of physicians this year, aiming for 100 meetings, to gather insights that will shape lifecycle strategies such as patent extensions, expanded indications and new formulations like IV delivery. Meanwhile, SK Biopharmaceuticals has invested in targeted TV and YouTube campaigns for its flagship epilepsy drug, Xcopri (cenobamate). Its 'Road to Reduction' campaign drew 9.37 million views in just one month, signaling the brand's growing visibility and leadership in the epilepsy treatment market.